| Verf.angabe: | Silvia Stacchiotti, Anna Maria Frezza, George D. Demetri, Jean-Yves Blay, Jyoti Bajpai, Giacomo G. Baldi, Elizabeth H. Baldini, Robert S. Benjamin, Sylvie Bonvalot, Judith V.M.G. Bovée, Dario Callegaro, Paolo G. Casali, Sandra P. D'Angelo, Elizabeth J. Davis, Angelo P. Dei Tos, Elizabeth G. Demicco, Jayesh Desai, Palma Dileo, Mikael Eriksson, Hans Gelderblom, Suzanne George, Rebecca A. Gladdy, Mrinal M. Gounder, Abha A. Gupta, Rick Haas, Andrea Hayes, Peter Hohenberger, Kevin B. Jones, Robin L. Jones, Bernd Kasper, Akira Kawai, David G. Kirsch, Eugenie S. Kleinerman, Axel Le Cesne, Roberta Maestro, Javier Martin Broto, Robert G. Maki, Aisha B. Miah, Emanuela Palmerini, Shreaskumar R. Patel, Chandrajit P. Raut, Albiruni R.A. Razak, Damon R. Reed, Piotr Rutkowski, Roberta G. Sanfilippo, Marta Sbaraglia, Inga-Marie Schaefer, Dirk C. Strauss, Sandra J. Strauss, William D. Tap, David M. Thomas, Annalisa Trama, Jonathan C. Trent, Winette T.A. van der Graaf, Winan J. van Houdt, Margaret von Mehren, Breelyn A. Wilky, Christopher D.M. Fletcher, Alessandro Gronchi, Rosalba Miceli, Andrew J. Wagner |
|---|
| Abstract: | Background - In ultra-rare sarcomas (URS) the conduction of prospective, randomized trials is challenging. Data from retrospective observational studies (ROS) may represent the best evidence available. ROS implicit limitations led to poor acceptance by the scientific community and regulatory authorities. In this context, an expert panel from the Connective Tissue Oncology Society (CTOS), agreed on the need to establish a set of minimum requirements for conducting high-quality ROS on the activity of systemic therapies in URS. - Methods - Representatives from > 25 worldwide sarcoma reference centres met in November 2020 and identified a list of topics summarizing the main issues encountered in ROS on URS. An online survey on these topics was distributed to the panel; results were summarized by descriptive statistics and discussed during a second meeting (November 2021). - Results - Topics identified by the panel included the use of ROS results as external control data, the criteria for contributing centers selection, modalities for ensuring a correct pathological diagnosis and radiologic assessment, consistency of surveillance policies across centers, study end-points, risk of data duplication, results publication. Based on the answers to the survey (55 of 62 invited experts) and discussion the panel agreed on 18 statements summarizing principles of recommended practice. - Conclusions - These recommendations will be disseminated by CTOS across the sarcoma community and incorporated in future ROS on URS, to maximize their quality and favor their use as control data when results from prospective studies are unavailable. These recommendations could help the optimal conduction of ROS also in other rare tumors. |
|---|
Online-Ressource
